【摘要】：目的:為了研究重組人血小板生成素(rhTPO)誘導(dǎo)小鼠反應(yīng)性血小板增多癥的病理變化。方法:將48只4周齡SPF級(jí)BALB/c小鼠,隨機(jī)分為rhTPO組和對(duì)照組,各24只。rhTPO組每只小鼠每日腹腔注射rhTPO 500μg/(kg·d),0.3 ml/只,對(duì)照組每只小鼠每日腹腔注射生理鹽水0.3 m L/只,連續(xù)注射10 d。實(shí)驗(yàn)第3、5、7和10天,取2組小鼠各6只拉頸處死,檢測(cè)兩組小鼠的外周血細(xì)胞數(shù)量、血小板(platelet,PLT)聚集實(shí)驗(yàn)(platelet aggregation test,PAgT)、血小板ATP釋放試驗(yàn)、血漿D-二聚體(D-dimer)濃度測(cè)定、小鼠血栓表現(xiàn)的觀察、骨髓活檢、脾、肝系數(shù)及脾、肝病理檢查。結(jié)果:rhTPO組PLT數(shù)量在第3天明顯高于對(duì)照組(P0.05),在第5、7和10天明顯高于對(duì)照組(P0.01)。rhTPO組5 min內(nèi)最大凝集率和血小板ATP釋放量在3、5、7和10天與對(duì)照組均無(wú)統(tǒng)計(jì)學(xué)差異(P0.05)。rhTPO組血漿D-dimer濃度在第3、5、7和10天明顯逐漸升高(P0.01),在第3天明顯高于對(duì)照組(P0.05),在第5、7和10天明顯高于對(duì)照組(P0.01)。2組小鼠均無(wú)血栓表現(xiàn)。rhTPO組在第3、5、7和10天巨核細(xì)胞大量增生,體積增大,且隨時(shí)間日益明顯。rhTPO組脾系數(shù)在第5、7天均明顯高于對(duì)照組(P0.05),在第10 d明顯高于對(duì)照組(P0.01),rhTPO組肝系數(shù)在第10天明顯高于對(duì)照組(P0.05)。rhTPO組脾臟巨核系和脾體積在第3天內(nèi)不變,但脾臟巨核系在第5、7和10天逐漸增生,第10天尚可見(jiàn)紅系增生,脾體積在第5、7和10天逐漸增大。肝臟在第10天可見(jiàn)紅系、粒系和巨核系增生且體積增大。結(jié)論:rhTPO誘導(dǎo)小鼠反應(yīng)性血小板增多癥的病理變化:骨髓中巨核細(xì)胞大量增生,外周血PLT數(shù)量急劇升高,但生成的PLT功能正常,初期,脾、肝未發(fā)生病理變化,中后期可刺激脾、肝先后髓外造血,體積先后增大。中后期可刺激脾臟巨核系逐漸增生,后期尚可見(jiàn)紅系增生,脾體積也逐漸增大。肝在后期且可見(jiàn)紅系、粒系和巨核系三系增生且體積增大。
[Abstract]:Aim: to study the pathological changes of reactive thrombocytosis induced by recombinant human thrombopoietin (rhTPO) in mice. Methods: Forty-eight 4-week-old SPF BALB/c mice were randomly divided into two groups: rhTPO group and control group, 24 mice in the rhTPO group were intraperitoneally injected with rhTPO 500 渭 g / (kg d), 0.3 ml/ daily. Each mouse in the control group was intraperitoneally injected with normal saline 0.3 mL / day for 10 days. On the 7th and 10th day of the experiment, 6 mice in each group were killed by neck pulling. The number of peripheral blood cells (PBMC), platelet aggregation test (platelet aggregation test,PAgT) and platelet ATP release test were detected in both groups. Plasma concentration of D-dimer (D-dimer), observation of thrombosis in mice, bone marrow biopsy, spleen, liver coefficient and spleen, liver pathological examination. Results: the number of PLT in the rhTPO group was significantly higher than that in the control group on the 3rd day (P0.05), and on the 7th and 10th day in the rhTPO group, it was significantly higher than that in the control group (P0.01). RhTPO group). On the 7th and 10th day, there was no significant difference between the control group and the control group (P0.05). The plasma D-dimer concentration in the). RhTPO group increased gradually on the 7th and 10th day (P0.01), and on the third day, it was significantly higher than that in the control group (P0.05). On the 7th and 10th day, the number of megakaryocytes in the rhTPO group was significantly higher than that in the control group (P0.01). The spleen coefficient of rhTPO group was significantly higher than that of control group on the 7th day (P0.05), and higher than that of control group (P0.01) on the 10th day. The liver coefficient of the rhTPO group was significantly higher than that of the control group on the 10th day (P0.05) the splenic megakaryocyte system and splenic volume in the). RhTPO group did not change at the 3rd day, but the splenic megakaryocytic system gradually proliferated on the 7th and 10th day, and the erythroid proliferation was observed on the 10th day. The volume of spleen gradually increased on the 7th and 10th day. Erythroid, granulocyte and megakaryocyte proliferated and enlarged in the liver on day 10. Conclusion: the pathological changes of reactive thrombocytopenia induced by rhTPO: the megakaryocyte proliferation in bone marrow and the number of PLT in peripheral blood increased sharply, but the function of PLT was normal, and no pathological changes occurred in spleen and liver at the initial stage. The middle and late stage can stimulate spleen, liver successively extramedullary hematopoiesis, volume successively increase. The splenic megakaryocyte was gradually proliferated in the middle and late stage, and the erythroid proliferation was seen in the later stage, and the splenic volume increased gradually. The erythroid, granulocyte and megakaryocyte were proliferated and enlarged in the later stage of liver.
【作者單位】： 湖北理工學(xué)院醫(yī)學(xué)院;黃石市中心醫(yī)院血液內(nèi)科;
【基金】：湖北省教育廳科技研究計(jì)劃指導(dǎo)項(xiàng)目(編號(hào):B2014027)
【分類(lèi)號(hào)】：R558.3

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張景,古麗;繼發(fā)性血小板增多癥1例[J];罕少疾病雜志;2002年02期

2 本刊編輯部;;系列問(wèn)答132——何謂血小板增多癥,與藥物是否有關(guān)?[J];藥物不良反應(yīng)雜志;2009年05期

3 馬沛然 ,李達(dá)權(quán) ,羅天慶;反應(yīng)性血小板增多癥[J];山東醫(yī)學(xué)院學(xué)報(bào);1980年02期

4 萬(wàn)樹(shù)棟;極度反應(yīng)性血小板增多癥一例報(bào)道[J];第二軍醫(yī)大學(xué)學(xué)報(bào);1989年03期

5 李紅，，趙萍;血小板增多癥一663例病因分析[J];寧夏醫(yī)學(xué)院學(xué)報(bào);1995年04期

6 陳皙;段美麗;;血小板增多癥診治進(jìn)展[J];山東醫(yī)藥;2013年48期

7 吳潔;任燕梅;;繼發(fā)性血小板增多癥669例原因分析[J];山西醫(yī)藥雜志;2013年12期

8 馬明信;;血小板增多癥能治好嗎[J];家庭醫(yī)藥;2007年09期

9 王鑒,吳倩倩;繼發(fā)性血小板增多癥26例[J];貴陽(yáng)醫(yī)學(xué)院學(xué)報(bào);2001年05期

10 李渝,張琳琳;以多臟器血栓形成為首發(fā)表現(xiàn)的血小板增多癥1例[J];臨床血液學(xué)雜志;2002年06期

相關(guān)會(huì)議論文 前3條

1 劉巧;孫先玲;畢業(yè);李哲;楊波;;血小板單采術(shù)在治療血小板增多癥中的應(yīng)用[A];中國(guó)輸血協(xié)會(huì)第四屆輸血大會(huì)論文集[C];2006年

2 虞飛燕;;海島居民繼發(fā)性血小板增多癥52例分析[A];2007年浙江省血液病學(xué)術(shù)年會(huì)論文匯編[C];2007年

3 劉凌;龐纓;葉絮;周旭紅;馮瑩;;原發(fā)性血小板增多癥血栓形成的相關(guān)因素研究[A];中華醫(yī)學(xué)會(huì)血液學(xué)分會(huì)第十三屆全國(guó)血栓與止血學(xué)術(shù)會(huì)議暨“血栓栓塞性疾�。ㄑㄅc止血）基礎(chǔ)與臨床研究進(jìn)展”論文摘要匯編及學(xué)習(xí)班講義[C];2011年

相關(guān)重要報(bào)紙文章 前1條

1 陶春祥;TPO診斷治療血小板疾病的研究進(jìn)展[N];中國(guó)醫(yī)藥報(bào);2003年

相關(guān)碩士學(xué)位論文 前1條

1 吳敏捷;抗Hp治療胃粘膜相關(guān)淋巴組織淋巴瘤繼發(fā)血小板增多癥一例并文獻(xiàn)復(fù)習(xí)[D];山西醫(yī)科大學(xué);2011年

本文編號(hào)：2364251